Golden bull award ceremony of listed companies, leading the biomedical industry!

[China Pharmaceutical network industry trends] on November 15, the 20th China Listed Company Golden COW award ceremony and forum was held in Chengdu, Sichuan Province 260 listed companies and their executives won seven golden cow awards Among them, biomedical industry accounts for a large proportion Among the listed companies that won the 2017 golden bull investment value award, the number of listed companies involved in chemical products, medical medicine, beverage manufacturing and other industries exceeded 10 In addition, this activity added "China Listed Company Golden COW foundation industry evergreen Award" to commend the outstanding companies in the past 20 years Guodian power, Tongrentang, Yanhu Co., Ltd., Yanzhou Coal Industry and Yili Co., Ltd were selected Biopharmaceutical industry is an important strategic emerging industry and pillar industry of our country It has high technology content and wide development prospect, but its R & D cycle is relatively long and its capital investment is huge, so it is also a big test for domestic pharmaceutical enterprises At the same time, "the 21st century is the century of biology", the global environment and the domestic policy spring breeze provide a continuous power for the rise of China's biomedical industry Some insiders said, "now China's market is very fair and open, and the support for biomedical field is also very good, which are very conducive to the development of domestic enterprises." It is understood that in recent years, with the rapid development of biopharmaceutical industry, more and more pharmaceutical enterprises, and even other industries have transformed into the market For example, step pharmaceutical released the announcement on strategic planning of biopharmaceutical industry on September 11, which mentioned that it would strive to build the whole biopharmaceutical industry chain, and constantly enhance the R & D strength of biopharmaceutical industry by building a platform, attracting talents and seeking cooperation At the same time, the company will take advantage of different advantages of domestic and foreign capital markets to enter the domestic and foreign capital markets Looking back at the domestic biopharmaceutical industry, taking Guangzhou as an example, since last year, the industry giants such as GE biology, semefei, Merck, Baiji Shenzhou, and Nuo Cheng Jianhua have settled here, focusing on a large number of experimental research and development institutions, biomedical talents and platforms At the round table meeting, experts in the industry pointed out that the current biopharmaceutical industry has a promising future, but it should be noted that the sustainability of the development plan should be strengthened to promote the development of the biopharmaceutical industry for a long time Among them, on the one hand, we should pay attention to the sustainability of the relevant institutional environment such as talent policy; on the other hand, we should pay attention to the improvement of the financial chain and enhance its sustainability The industry also mentioned that Guangzhou needs to pay attention to the development of biomedical device industry Although the market scale of biomedical device industry in China is not large enough, its growth rate is very fast in recent years According to statistics, in developed countries, the relationship between biomedicine and medical devices is 1:1, but in China, the current proportion is only 7:1, the proportion of biomedical devices is not high, there is still a lot of room for development Therefore, for the domestic biomedical device industry, there is still a lot of room for progress to break the situation of relying on imported equipment In addition, for biomedical state-owned enterprises and private enterprises, some insiders said, "state-owned enterprises make a great contribution to the people's livelihood, while private enterprises have a greater potential for development, because their research direction, development direction, and flexibility of enterprises are far more than state-owned enterprises."